Trade Y-mAbs Therapeutics, Inc. - YMAB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 15.23 |
| Open | 14.28 |
| 1-Year Change | 143.27% |
| Day's Range | 14.28 - 15.33 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 14.80 | 0.11 | 0.75% | 14.69 | 15.36 | 14.24 |
| Apr 24, 2024 | 15.23 | 0.11 | 0.73% | 15.12 | 15.35 | 14.95 |
| Apr 23, 2024 | 15.31 | 0.24 | 1.59% | 15.07 | 16.32 | 14.77 |
| Apr 22, 2024 | 15.11 | 0.07 | 0.47% | 15.04 | 15.82 | 14.84 |
| Apr 19, 2024 | 15.08 | 0.26 | 1.75% | 14.82 | 15.30 | 14.43 |
| Apr 18, 2024 | 14.94 | 0.07 | 0.47% | 14.87 | 15.34 | 14.74 |
| Apr 17, 2024 | 15.05 | 0.02 | 0.13% | 15.03 | 15.34 | 14.85 |
| Apr 16, 2024 | 15.11 | 0.97 | 6.86% | 14.14 | 15.58 | 14.14 |
| Apr 15, 2024 | 14.86 | 1.15 | 8.39% | 13.71 | 14.90 | 13.71 |
| Apr 12, 2024 | 14.32 | 0.38 | 2.73% | 13.94 | 14.61 | 13.94 |
| Apr 11, 2024 | 14.60 | 0.70 | 5.04% | 13.90 | 14.75 | 13.83 |
| Apr 10, 2024 | 13.73 | 0.25 | 1.85% | 13.48 | 13.92 | 13.29 |
| Apr 9, 2024 | 14.04 | -0.23 | -1.61% | 14.27 | 14.46 | 13.77 |
| Apr 8, 2024 | 14.42 | -0.03 | -0.21% | 14.45 | 14.84 | 13.98 |
| Apr 5, 2024 | 14.44 | 0.17 | 1.19% | 14.27 | 14.98 | 14.12 |
| Apr 4, 2024 | 14.49 | 0.17 | 1.19% | 14.32 | 14.73 | 14.22 |
| Apr 3, 2024 | 14.36 | -0.16 | -1.10% | 14.52 | 14.54 | 13.91 |
| Apr 2, 2024 | 14.71 | -0.27 | -1.80% | 14.98 | 15.02 | 14.23 |
| Apr 1, 2024 | 16.16 | 0.09 | 0.56% | 16.07 | 17.23 | 15.75 |
| Mar 28, 2024 | 16.23 | 0.28 | 1.76% | 15.95 | 16.45 | 15.85 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Y-mAbs Therapeutics, Inc. Company profile
About Y-mAbs Therapeutics Inc
Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody based therapeutic products for the treatment of cancer. Its product pipeline includes DANYELZA (naxitamab-gqgk), which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor, or GM-CSF,for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Y-mAbs Therapeutics Inc revenues increased 68% to $34.9M. Net loss decreased 54% to $55.3M. Revenues reflect License revenue increase of 59% to $32.9M. Lower net loss reflects Foreign Exchange Gain/LossNon-Business increase from $576K (expense) to $1.9M (income), Licensing royalties decrease of 90% to $210K (expense), Research and development - Balancing val decrease of 2% to $83.5M (expense).
| Industry: | Bio Therapeutic Drugs |
230 Park Avenue
Suite 3350
NEW YORK
NEW YORK 10169
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com